Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

173.53
Delayed Data
As of Sep 26
 -1.27 / -0.73%
Today’s Change
130.09
Today|||52-Week Range
176.85
+6.90%
Year-to-Date
Wall Street Sells Off on Worries Over Clinton-Trump Showdown
Sep 26 / TheStreet.com - Paid Partner Content
Stock Market News for September 21, 2016
Sep 21 / Zacks.com - Paid Partner Content
Biotech ETFs May Be a Prescription for Investment Success, Especially If Trump Become...
Sep 26 / TheStreet.com - Paid Partner Content
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Sep 19 / Zacks.com - Paid Partner Content
As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble?
Sep 26 / Zacks.com - Paid Partner Content
Is This New Market the Biggest Investment Idea of the Decade?
Sep 17 / MotleyFool.com - Paid Partner Content
Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
Sep 26 / TheStreet.com - Paid Partner Content
Novartis Reports Positive Phase II Data on Migraine Drug
Sep 16 / Zacks.com - Paid Partner Content
Stock Market News for September 26, 2016
Sep 26 / Zacks.com - Paid Partner Content
Stock Market News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content
Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep 26 / Zacks.com - Paid Partner Content
Takeda earmarks $15bn for US pharma acquisitions
Sep 13 / FT.com - Paid Partner Content
Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?
Sep 23 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Spectrum Pharmaceuticals, Amgen, AbbVie and Vertex...
Sep 13 / Zacks.com - Paid Partner Content
New Setback for Sanofi's Lantus Increases Need for M&A
Sep 22 / TheStreet.com - Paid Partner Content
Biotech Stocks Bounce Back in Monday Trading: 3 Picks
Sep 13 / Zacks.com - Paid Partner Content
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Sep 21 / Zacks.com - Paid Partner Content